Provided by Tiger Fintech (Singapore) Pte. Ltd.

Salarius Pharmaceuticals Inc

0.6900
+0.0000
Post-market: 0.71680.0268+3.88%16:00 EDT
Volume:37.26K
Turnover:25.87K
Market Cap:1.47M
PE:-0.12
High:0.7199
Open:0.6810
Low:0.6623
Close:0.6900
Loading ...

Company Profile

Company Name:
Salarius Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
2
Office Location:
2450 Holcombe Blvd.,Suite X,Houston,Texas,United States
Zip Code:
77021
Fax:
- -
Introduction:
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Directors

Name
Position
David J. Arthur
President, Chief Executive Officer and Director
William K. McVicar
Chairman
Arnold C. Hanish
Director
Bruce J. McCreedy
Director
Jonathan Lieber
Director
Paul Lammers M. D.
Director
Tess Burleson
Director

Shareholders

Name
Position
David J. Arthur
President, Chief Executive Officer and Director
Mark J. Rosenblum
Executive Vice President of Finance and Chief Financial Officer